Findings

What do systematic reviews say?

4,860 questions · 64,864 findings · 4,913 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 21.4%GRADE not reported 3,491 · 5.4%Very low 16,300 · 25.1%Low 17,338 · 26.7%Moderate 10,900 · 16.8%High 2,966 · 4.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings 2: Immunotherapies vs placebo

(513) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 369 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(939) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2674 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(2384) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 3692 participants
Low

Potassium paraaminobenzoate vs placebo

Outcomes ( · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional interferon alpha‐2B vs Normal saline

Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional interferon alpha‐2B vs Normal saline

Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Very low

Injectional interferon alpha‐2B vs Normal saline

Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
RR 0.63 [0.22, 1.76]
1 study · 117 participants
Very low

Injectional nicardipine vs Normal saline

Outcomes ( · men with chronic Peyronie's disease (plaques without calcification)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional nicardipine vs Normal saline

Patient‐reported ability to have intercourse · men with chronic Peyronie's disease (plaques without calcification)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional nicardipine vs Normal saline

Quality of life · men with chronic Peyronie's disease (plaques without calcification)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional nicardipine vs Normal saline

Treatment‐related adverse effects · men with chronic Peyronie's disease (plaques without calcification)

It is very uncertain whether injectional nicardipine changes treatment‐related adverse effects compared with saline (very low certainty).

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
RR 2.82 [0.12, 66.62]
1 study · 62 participants
Very low

Injectional nicardipine vs Normal saline

Degree of penile curvature · men with chronic Peyronie's disease (plaques without calcification)

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

Injectional nicardipine vs Normal saline

Treatment discontinuation · men with chronic Peyronie's disease (plaques without calcification)

It is very uncertain whether injectional nicardipine changes discontinuation from treatment compared with saline (very low certainty).

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
RR 0.71 [0.25, 2.05]
1 study · 74 participants
Very low

Injectional betamethasone vs Normal saline

Outcomes ( · men with Peyronie's disease (not defined)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Potassium paraaminobenzoate vs placebo

Patient‐reported ability to have intercourse · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…

Potassium paraaminobenzoate showed no clear difference in patient‐reported ability to have intercourse compared with placebo (low certainty).

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
RR 1.19 [0.87, 1.62]
1 study · 75 participants
Low

Injectional betamethasone vs Normal saline

Patient‐reported ability to have intercourse · men with Peyronie's disease (not defined)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional betamethasone vs Normal saline

Quality of life · men with Peyronie's disease (not defined)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional betamethasone vs Normal saline

Treatment‐related adverse effects (long‐term) · men with Peyronie's disease (not defined)

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Injectional betamethasone vs Normal saline

Degree of penile curvature · men with Peyronie's disease (not defined)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional betamethasone vs Normal saline

Treatment discontinuation · men with Peyronie's disease (not defined)

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low